🇺🇸 FDA
Pipeline program

rasagiline

14630

Phase 3 small_molecule terminated

Quick answer

rasagiline for Restless Legs Syndrome is a Phase 3 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Teva Pharma GmbH
Indication
Restless Legs Syndrome
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials